Fella Health Review (2026): Men’s GLP-1 Platform, App and Pricing

Fella Health is the only major US GLP-1 telehealth platform built exclusively for men. That is a genuine product decision, not marketing language — the programme integrates testosterone screening, male-specific coaching, and metabolic health markers that most gender-neutral platforms ignore. It is also, as of May 2026, operating under an active federal lawsuit filed by Novo Nordisk over its compounded semaglutide marketing. Both facts matter for anyone considering signing up.

This review covers what Fella actually offers today, at what price, under what legal constraints, and what the sign-up and support experience looks like in practice. It is built from public sources, published pricing, and publicly available court records. This is an editorial-only review — clinical scoring is deferred to the post–medical-reviewer phase.

Fella Health at a glance

How we review providers: every platform is scored against the same five-question review methodology. Metabolic Ledger is reader-supported — we may earn a commission if you start a programme through some links, at no extra cost to you (affiliate disclosure). This is an editorial review, not medical advice.

What Fella is — and who it is designed for

Fella launched in 2019 under the premise that weight-loss medicine for men is a different clinical and behavioural problem from weight-loss medicine for women. The platform does not treat women, and that is by design.

Men carry more visceral adipose tissue, are less likely to seek medical help proactively, tend to respond differently to standard behavioural coaching models, and frequently present with low testosterone alongside metabolic dysfunction — a co-morbidity that women’s programmes do not need to account for. Fella’s programme addresses this directly: every member gets a metabolic lab panel that includes testosterone markers, and the platform offers Enclomiphene (an oral testosterone stimulant) alongside GLP-1 medications for men who screen as testosterone-deficient.

The coaching model is also male-specific. Bi-weekly video check-ins use coaches trained in male behavioural patterns around food and exercise. Community forums, where they exist, are all-male. Whether that specialisation is worth the price premium over a gender-neutral provider is the question this review is designed to help you answer.

Who Fella is designed for: Men aged 18–65, BMI 27 or higher, who want their GLP-1 prescription bundled with ongoing coaching and who are comfortable with the legal uncertainty around compounded medications in 2026.

Who it is not designed for: Women. Men who want the lowest possible cash-pay price with minimal frills. Men who require insurance billing or a very fast first shipment.

Compounding status in 2026 — the litigation reality

This is the most important section of this review. Read it before making a sign-up decision.

The Novo Nordisk lawsuit. On August 4, 2025, Novo Nordisk A/S and Novo Nordisk Inc. filed a federal complaint against Aios Inc. (d/b/a Fella Health and Delilah), Fella Medical Group P.A., and Fella Medical Group P.C. in the US District Court for the Northern District of California (case 3:25-cv-06560). The claims arise under the Lanham Act (15 U.S.C. §1125) — trademark and false advertising provisions — targeting Fella’s marketing of compounded semaglutide. This is the same legal theory Novo used against other compounding-dependent platforms in its 2025 enforcement wave.

As of May 2026, the case has not been settled, dismissed, or resolved by consent order. After Novo declined to proceed before a Magistrate Judge in September 2025, the case was reassigned to a District Judge. An initial Case Management Conference was scheduled for November 6, 2025. No final judgment or settlement has appeared in public dockets as of the time of this writing.

What Fella is currently selling. Fella’s own website states, as of May 2026: “We offer compounded medications and Zepbound®. Compounded medications are prepared by licensed pharmacies and are not FDA-approved.” Fella is therefore still operating a compounded pathway — presumably under the §503A(b)(1)(D) significant-difference framing that surviving providers use — alongside the brand-name Zepbound option.

Why this matters for potential patients. The 503A compounding window is the only active legal pathway for compounded GLP-1s post-shortage. The FDA’s April 30, 2026 proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk substances list does not directly close §503A, but it signals continued regulatory pressure. Fella, unlike Henry Meds, is defending an active federal trademark case while operating its compounded programme. If the case reaches an adverse judgment or forces a Hims-style settlement, Fella’s compounded pathway would likely close. Patients mid-programme would need to transition to brand-name products at higher cost or transfer to a different provider.

This is not a reason to definitively avoid Fella. It is material information that any prescribing or purchasing decision should account for. See our compounding tracker for the current enforcement landscape and the FDA compounding cliff explainer for context on the underlying regulatory framework.

Pricing — what you actually pay

Fella does not publish headline prices on its main website; it routes enquirers through a quiz. Based on independent review sites and published comparison data verified in May 2026:

On branded products, Fella's pricing does not clearly undercut the manufacturers' direct-pay programmes (NovoCare Wegovy at $349/month flat; LillyDirect Zepbound at $299–$449/month by dose, as of May 2026).

Lab work: An initial metabolic assessment is included. For patients without insurance coverage of labs, a separate $60 lab fee may apply.

HSA/FSA: Accepted. No insurance billing.

All prices are sourced from published reviews and comparison sources; Fella’s in-quiz pricing may differ. Verify at fellahealth.com before committing.

Does the men’s health specialisation add value?

For a specific subset of Fella’s patient population, yes — meaningfully so.

Men who are also dealing with low testosterone (a common co-morbidity in men with elevated BMI) get a programme that addresses both conditions in parallel. Fella’s prescribers can add Enclomiphene — starting at $149/month — to a GLP-1 programme without requiring a separate referral. Testosterone and GLP-1 treatments interact: dropping weight improves endogenous testosterone production, and restoring testosterone improves lean muscle retention during rapid weight loss. A platform that monitors both simultaneously has a clinical logic.

The coaching model is also calibrated to male motivational patterns. Multiple independent reviews note that Fella’s coaches incorporate strength training guidance, resistance training targets, and protein optimisation alongside the standard lifestyle advice. That is not unique to Fella, but it is more consistently executed here than on gender-neutral platforms.

The caveat is that the male-specific framing is baked into the price. You are paying a premium over simpler compounding-only platforms like Henry Meds. Whether that premium is worth it depends on whether you will actually use the coaching. If you want the medication and nothing else, a lower-cost option is better value.

Sign-up and intake

The onboarding process is fully remote and takes 8–10 days from initial quiz to first medication shipment, assuming lab work is completed promptly.

Step 1: 2-minute online quiz. Basic health and weight information to generate a pre-approval. This is a soft gate, not a clinical assessment.

Step 2: Metabolic assessment and lab work. Fella orders a free comprehensive lab panel — including metabolic markers and testosterone levels — through local Quest or LabCorp draw sites or an optional at-home kit. This is a genuine clinical step, not a box-tick.

Step 3: Clinician consultation. A board-certified prescriber reviews your labs and medical history via asynchronous or synchronous consultation and creates your treatment plan.

Step 4: Medication shipped. Compounded medication or brand-name product ships to your home. First shipment typically arrives within 3–7 business days of prescription confirmation.

Ongoing: Bi-weekly video coaching sessions with a named health coach. Monthly prescriber check-ins for dose adjustment. Continuous supply with no dose-based price increases on compounded formulations.

Formulary — what Fella currently offers

Weight loss (GLP-1):

• Compounded semaglutide (injectable, weekly) — same active ingredient as Ozempic/Wegovy; not FDA-approved
• Compounded tirzepatide (injectable, weekly) — same active ingredient as Mounjaro/Zepbound; not FDA-approved
• Zepbound (brand-name tirzepatide, injectable, weekly) — FDA-approved

Testosterone support:

• Enclomiphene (oral) — from $149/month; stimulates natural testosterone production without suppressing fertility

Longevity / metabolic:

• Metformin — from $45/month
• Rapamycin — from $99/month
• NAD+ — from $99/month

Fella does not currently offer compounded oral semaglutide or compounded oral tirzepatide, which some competitors (Henry Meds, Eden) include in their formularies.

Support quality

Fella’s support architecture is its clearest differentiator from price-leader platforms. The bi-weekly video coaching model — with named coaches rather than app-based chatbots — is a genuine service that most low-cost GLP-1 providers do not replicate. Independent reviews consistently describe coaches as responsive and knowledgeable about male physiology.

Phone support is available at (415) 649-5531, and multiple reviews describe customer service as responsive when reachable. The caveat is that BBB complaints — 13 in three years, with 5 in the last 12 months — cluster around billing and cancellation friction rather than clinical care quality. The clinical support appears solid; the administrative support has gaps.

Fella’s claimed outcome data: members lose 5% of body weight by month 3 and 10.4% by month 6 on average. These are self-reported figures, not RCT data, and should be evaluated with appropriate scepticism. They are in line with published compounded semaglutide efficacy data.

Cancellation

Fella allows cancellation at any time. The official policy:

• A 72-hour full-refund window exists immediately after sign-up
• After 72 hours, fees already paid are non-refundable except under the money-back guarantee
• The 6-month guarantee refund window opens between days 181 and 210

In practice, cancellation has been a friction point for some members. BBB complaints include accounts of automatic subscription reactivation after cancellation requests, charges continuing after cancellation, and difficulty reaching support to confirm cancellation. One documented complaint describes an account reactivated without consent, resulting in duplicate charges.

Practical recommendation: cancel in writing via email to Fella support, request a written confirmation, and follow up if no confirmation is received within 48 hours. Screenshot your cancellation confirmation.

Best for / Not for

Best for:

• Men with elevated BMI who also have or suspect low testosterone
• Men who will engage with bi-weekly coaching and want structured lifestyle support alongside medication
• Men comfortable with the current legal status of §503A compounded GLP-1s who are willing to accept the Novo Nordisk litigation risk
• Men who want a 6-month money-back guarantee as a backstop

Not for:

• Women (categorically excluded)
• Men who want the lowest possible cash-pay price for medication only — Henry Meds or Eden are less expensive
• Men who need insurance billing — Fella is cash-pay only
• Men who are risk-averse about the Novo Nordisk litigation cloud over Fella’s compounded programme
• Men in Alaska, Hawaii, Alabama, or Mississippi — Fella does not currently serve those states

Fella vs Henry Meds — two compounding specialists compared

Both Fella and Henry Meds occupy the compounding-specialist end of the GLP-1 market. Their models are structurally different.

The headline comparison: Henry Meds is cheaper for the medication alone, offers oral formulations Fella does not, and has not been named in confirmed active federal litigation as of May 2026. Fella is more expensive but bundles coaching, lab work, and testosterone management into the programme — and those additions have real value for men who use them.

On litigation exposure: Henry Meds’ clean litigation record is an advantage, but neither provider’s compounded programme is insulated from future enforcement. Fella’s named-defendant status in the Novo suit is a more concrete near-term risk.

See the full provider comparison table for how Fella and Henry Meds stack up against Mochi, Eden, Ro, and others.